Global Splenomegaly Therapeutics Market Will Grow at a CAGR of Over 3% During 2019-2023 | Technavio

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190422005214/en/

The global splenomegaly therapeutics market will post a CAGR of over 3% during 2019-2023 (Graphic: Business Wire)

Global splenomegaly therapeutics market size will grow by USD 2.06 billion during 2019-2023, at a CAGR of over 3%. Splenomegaly is a clinical manifestation. Spleen enlargement can be caused by different reasons such as increased venous pressure, increased immune functions, and abnormal trafficking patterns of clonal hematopoietic cells. This information has led the researchers to study the mechanism of action and disease-specific factors for splenomegaly because this understanding helps them to develop many JAK-2 protein inhibitors that can effectively reduce spleen volume.

Increasing demand for targeted therapy

The specific mechanism of action of targeted therapy helps in minimizing the side effects of drugs. This is done by singling out specific receptors present in cancer cells, which protects the peripheral healthy cells from damage. The growing research on targeted therapy also helps in the clinical development of several JAK-2 inhibitors. JAK-2 inhibitors reduce the spleen size. At present, there are many targeted therapy agents under the late stages of clinical development. The primary outcome of these therapies is spleen size reduction.

Request for a FREE sample and get selected illustrations, table of contents, list of exhibits, and example pages from this report.

“The growing awareness about the symptoms associated with the disease and early diagnosis and management of splenomegaly will drive splenomegaly therapeutics market growth in North America. Additionally, the availability of full-time reimbursement for high-priced drugs in the US will also drive the growth of the market in North America”, says an analyst at Technavio.

Vendors are increasingly spending on research activities and focusing on advanced molecular biology to understand the reason behind the growing incidence and etiology of splenomegaly. This helps them to develop target therapy and drugs. These drugs are introduced in the market when they are approved by various healthcare agencies. This will boost the availability of splenomegaly drugs in the market.

View snapshot of the report for a more detailed overview of the market and the segmentations covered in this report

This splenomegaly therapeutics industry research report provides an in-depth analysis of the major drivers, upcoming trends, and challenges that will impact market growth over the forecast period. The report analyzes the competitive landscape and offers details on several splenomegaly therapeutics manufacturers including -

• GlaxoSmithKline plc
• Incyte Corporation
• Merck & Co.
• Novartis AG
• Sanofi

Some of the key topics covered in the report include:

Market Landscape

• Market ecosystem
• Market characteristics
• Market segmentation analysis

Market Sizing

• Market definition
• Market size and forecast

Five Forces Analysis

Market Segmentation

Geographical Segmentation

• Regional comparison
• Key leading countries

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

• Vendors covered
• Vendor classification
• Market positioning of vendors
• Competitive scenario

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. Technavio’s report library consists of more than 10,000 reports covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies.

Please contact our media team at media@technavio.com for more information

View source version on businesswire.com: https://www.businesswire.com/news/home/20190422005214/en/